Pharmacokinetics and anticoagulant properties of the factor VIIa-tissue factor inhibitor recombinant Nematode Anticoagulant Protein c2 following subcutaneous administration in man. Dependence on the stoichiometric binding to circulating factor X.
Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) is a potent (K(i) =10 pM), inhibitor of the factor VIIa/tissue factor (fVIIa/TF) complex that requires the prerequisite binding to zymogen or activated factor X (fX). In two double blind, place-bo-controlled, sequential dose-escalation phase I studies, rNAPc2 was found to be safe and well tolerated following single and repeat subcutaneous administrations in healthy human male volunteers at doses ranging from 0.3 to 5 micro g/kg. There was a dose-dependent elevation of the prothrombin time reaching almost 4-fold above the baseline value in the highest dose group that directly correlated with rNAPc2 plasma concentration. In contrast, there was little or no effect on the activated partial thromboplastin time, thrombin time or template bleeding time. The pharmacokinetic behavior of rNAPc2 revealed a dose-independent and prolonged elimination half-life (t(1/2)beta) with a mean of >50 hours. A high affinity interaction between rNAPc2 and plasma fX was shown to be essential for the prolonged t(1/2)beta in man using crossed immunoelectrophoresis and was confirmed by exploiting the considerably weaker interaction between rNAPc2 and bovine fX which resulted in an attenuated t(1/2)beta of approximately 1.5 hours in calves. The accumulated data suggests that rNAPc2 is safe and well tolerated following repeat subcutaneous administrations at doses up to 5 micro g/kg in healthy volunteers. In addition, the in vivo fate of rNAPc2 in man appears to be governed by its high affinity interaction with circulating fX. This data supports the continued development of this novel anticoagulant for the prevention and treatment of acute thrombotic disorders.
Corvas International, Inc., 3030 Science Park Road, San Diego, California, 92121, USA. vlasuk@adelphia.net
George P
GP
Vlasuk
Annette
A
Bradbury
Lily
L
Lopez-Kinninger
Sonia
S
Colón
Peter W
PW
Bergum
Steven
S
Maki
William E
WE
Rote
D000818:Animals; D000925:Anticoagulants / Q000008:administration & dosage / Q000276:immunology / Q000493:pharmacokinetics*; D001777:Blood Coagulation / Q000187:drug effects; D002417:Cattle; D004305:Dose-Response Relationship, Drug; D015942:Factor VIIa / Q000037:antagonists & inhibitors*; D005170:Factor X / Q000378:metabolism; D015801:Helminth Proteins / Q000008:administration & dosage* / Q000493:pharmacokinetics; D006801:Humans; D007518:Isoantibodies / Q000097:blood; D008297:Male; D010599:Pharmacokinetics; D011994:Recombinant Proteins; D013925:Thromboplastin / Q000037:antagonists & inhibitors*
D000925:Anticoagulants; D015801:Helminth Proteins; D007518:Isoantibodies; D011994:Recombinant Proteins; C400226:anti-coagulant protein C2, Ancylostoma caninum; D005170:Factor X; D013925:Thromboplastin; D015942:Factor VIIa